Tag Archives: nuevosinhibidores

[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][nectar_highlighted_text color_type="regular" style="full_text"]

Resistencia a ceftazidima/avibactam, meropenem/vaborbactam e imipenem/relebactam en bacilos gramnegativos MDR: mecanismos moleculares y pruebas de susceptibilidad.[/nectar_highlighted_text][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][text-with-icon icon_type="font_icon" icon="icon-book" color="Accent-Color"]

Gaibani, P.; Giani, T.; Bovo, F.; Lombardo, D.; Amadesi, S.; Lazzarotto, T.; Coppi, M.; Rossolini, G.M.; Ambretti, S. Resistance to Ceftazidime/Avibactam,
Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics
2022, 11, 628. https://doi.org/ 10.3390/antibiotics11050628

[/text-with-icon][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][vc_column_text]La resistencia a múltiples medicamentos (MDR) representa una grave amenaza global debido a la rápida propagación global y las limitadas opciones antimicrobianas para el tratamiento de infecciones difíciles de tratar (DTR). Recientemente, se han desarrollado nuevas combinaciones de β-lactámicos/inhibidores de β-lactamasa (βL-INH) para el tratamiento de infecciones por DTR debidas a patógenos gramnegativos MDR. Aunque los nuevos βL-INH mostraron actividades prometedoras in vitro e in vivo contra patógenos MDR, recientemente se han informado resistencias emergentes a estas nuevas moléculas. Esta resistencia se debe a varios mecanismos que incluyen deficiencias de porinas, aumento de la expresión de carbapenemasas y/o mutaciones enzimáticas. En esta revisión, se resumen los principales mecanismos relacionados con la resistencia a ceftazidima/avibactam, meropenem/vaborbactam e imipenem/relebactam en MDR. Los autores se enfocan en los mecanismos moleculares relacionados con la resistencia a estos nuevos fármacos, discuten sobre los principales métodos de detección y las pruebas de susceptibilidad de estos antimicrobianos.[/vc_column_text][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][image_with_animation image_url="3198" animation="Fade In" hover_animation="none" alignment="" border_radius="none" box_shadow="none" image_loading="default" max_width="100%" max_width_mobile="default"][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][nectar_cta btn_style="material" heading_tag="h6" text_color="#000000" link_type="regular" alignment="left" display="block" link_text="Artículo completo" url="https://www.mdpi.com/2079-6382/11/5/628"][/vc_column][/vc_row]

[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][vc_column_text]Int. J. Mol. Sci. 2020, 21, 9308; doi:10.3390/ijms21239308[/vc_column_text][nectar_highlighted_text color_type="regular" style="full_text"]

Nuevos inhibidores de carbapenemasas : mejorando la vía para los betalactámicos.

[/nectar_highlighted_text][vc_column_text]La resistencia a los carbapenémicos es un importante problema de salud mundial que compromete gravemente el tratamiento de infecciones causadas por patógenos nosocomiales. Se produce principalmente a través de la producción de carbapenemasas, como KPC, VIM, IMP, NDM, OXA, entre otras. Actualmente se están llevando a cabo ensayos clínicos para probar una nueva generación de inhibidores muy prometedores, junto con el avibactam, relebactam y vaborbactam recientemente aprobados.

Esta revisión resume los principales inhibidores de carbapenemasas más prometedores sintetizados hasta la fecha, así como su espectro de actividad y etapa actual de desarrollo. Este artículo se centra especialmente en las combinaciones de betalactámicos con inhibidores de betalactamasas que podrían usar para tratar infecciones causadas por patógenos productores de carbapenemasas de
prioridad crítica. La aparición de estas nuevas combinaciones supone un paso adelante en la lucha contra la resistencia a los antimicrobianos.[/vc_column_text][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/2" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][image_with_animation image_url="2601" animation="Fade In" hover_animation="none" alignment="right" img_link_large="yes" border_radius="none" box_shadow="none" image_loading="default" max_width="100%" max_width_mobile="default"][/vc_column][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/2" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][image_with_animation image_url="2602" animation="Fade In" hover_animation="none" alignment="right" img_link_large="yes" border_radius="none" box_shadow="none" image_loading="default" max_width="100%" max_width_mobile="default"][/vc_column][/vc_row][vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none" column_border_radius="none" column_link_target="_self" gradient_direction="left_to_right" overlay_strength="0.3" width="1/1" tablet_width_inherit="default" tablet_text_alignment="default" phone_text_alignment="default" column_border_width="none" column_border_style="solid" bg_image_animation="none"][nectar_cta btn_style="see-through" heading_tag="h6" button_color="default" link_type="regular" alignment="left" display="block" text="Artículo completo" url="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731173/"][/vc_column][/vc_row]